Share information and policies

BerGenBio has only one class of shares. The share is listed on Oslo Stock Exchange (Oslo Børs) under the ticker BGBIO.

BerGenBio has not developed a dividend policy. The Company is focusing on the development of novel pharmaceutical products and does not anticipate paying a cash dividend until sustainable profitability is achieved. The Company has not previously distributed any dividends to its shareholders.

The Company primarily uses equity as source for capital and financing of Research & Development of the Company’s assets in addition to nondilutive government grants funding. The Company will also explore other sources of capital.

For mandatory announcements relating to trades by primary insiders press here.
For a list of primary insiders please see here.

For mandatory announcements relating to large shareholdings press here.

The Company’s register of shareholders with the VPS is administrated by DNB:
DNB Bank ASA, Verdipapirservice
Dronning Eufemias gate 30
0191 OSLO
www.dnb.no

BerGenBio is audited by EY:
ERNST & YOUNG AS, organization number 976 389 387
Dronning Eufemias gate 6
0191 OSLO
www.ey.no

BerGenBio ASA

Visiting address:
Nygardsgaten 114
5008 Bergen

Postal address:
P.O. Box 2324, Møllendal
5867 Bergen

Organization number: 992 219 688
ISIN: NO 001 3251173
LEI: 213800TYYFXKYF3V2A23